An analysis of the baseline characteristics and outcomes, by responders and nonresponders, from the phase 3 study of (E7080) Lenvatinib in differentiated cancer of the thyroid (SELECT)

被引：0
|
作者：
Reuter, Christoph [1 ]
Yu, Xiaomin [1 ]
Baig, Mahadi [1 ]
Young, Louise [2 ]
Dutcus, Corina [1 ]
机构：
[1] Eisai Inc, Woodcliff Lake, NJ USA
[2] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
来源：
CLINICAL ENDOCRINOLOGY | 2018年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
185
引用
收藏
页码：45 / 46
页数：2
相关论文
共 39 条
  • [1] Baseline characteristics of responders and nonresponders from the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)
    Reuter, C.
    Yu, X.
    Baig, M.
    Dutcus, C. E.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S112 - S113
  • [2] Treatment-Emergent Hypertension and Efficacy in the Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT)
    Wirth, Lori J.
    Tahara, Makoto
    Robinson, Bruce
    Francis, Sanjeev
    Brose, Marcia S.
    Habra, Mouhammed Amir
    Newbold, Kate
    Kiyota, Naomi
    Dutcus, Corina E.
    Mathias, Elton
    Guo, Matthew
    Sherman, Steven I.
    Schlumberger, Martin
    CANCER, 2018, 124 (11) : 2365 - 2372
  • [3] ANALYSES OF A PHASE 3, MULTICENTER, DOUBLEBLIND, PLACEBO- CONTROLLED TRIAL OF LENVATINIB (E7080) IN PATIENTS WITH 131-I-REFRACTORY DIFFERENTIATED THYROID CANCER (SELECT)
    不详
    EUROPEAN THYROID JOURNAL, 2014, 3 : 12 - 250
  • [4] A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-refractory differentiated thyroid cancer (SELECT)
    Schlumberger, M.
    Tahara, M.
    Wirth, L.
    Robinson, B.
    Brose, M.
    Elisei, R.
    Dutcus, C.
    de las Heras, B.
    Zhu, J.
    Habra, M.
    Newbold, K.
    Shah, M. H.
    Hoff, A. O.
    Gianoukakis, A. G.
    Kiyota, N.
    Taylor, M.
    Kim, S-B
    Krzyzanowska, M.
    Sherman, S., I
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 119 - 119
  • [5] A Phase 2 Trial of Lenvatinib (E7080) in Advanced, Progressive, Radioiodine-Refractory, Differentiated Thyroid Cancer: A Clinical Outcomes and Biomarker Assessment
    Cabanillas, Maria E.
    Schlumberger, Martin
    Jarzab, Barbara
    Martins, Renato G.
    Pacini, Furio
    Robinson, Bruce
    McCaffrey, Judith C.
    Shah, Manisha H.
    Bodenner, Donald L.
    Topliss, Duncan
    Andresen, Corina
    O'Brien, James P.
    Ren, Min
    Funahashi, Yasuhiro
    Allison, Roger
    Elisei, Rossella
    Newbold, Kate
    Licitra, Lisa F.
    Sherman, Steven I.
    Ball, Douglas W.
    CANCER, 2015, 121 (16) : 2749 - 2756
  • [6] A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 134I-refractory differentiated thyroid cancer (SELECT)
    Schlumberger, Martin
    Tahara, Makoto
    Wirth, Lori J.
    Robinson, Bruce
    Brose, Marcia S.
    Ellsel, Rossella
    Dutcus, Corina E.
    de las Hares, Begona
    Zhu, Junming
    Habra, Mouhamed Amir
    Newbold, Kate
    Shah, Manisha H.
    Hoff, Ana O.
    Gianoukakis, Andrew G.
    Kiyota, Naomi
    Taylor, Matthew Hiram
    Kim, Sung-Bae
    Krzyranowska, Monika K.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)
    Schlumberger, Martin
    Tahara, Makoto
    Wirth, Lori J.
    Robinson, Bruce
    Brose, Marcia S.
    Elisei, Rossella
    Dutcus, Corina E.
    de las Heras, Begoria
    Zhu, Junming
    Habra, Mouhammed Amir
    Newbold, Kate
    Shah, Manisha H.
    Hoff, Ana O.
    Gianoukakis, Andrew G.
    Kiyota, Naomi
    Taylor, Matthew Hiram
    Kim, Sung-Bae
    Krzyzanowska, Monika K.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
  • [8] A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas W.
    McCaffrey, Judith
    Newbold, Kate
    Allison, Roger
    Martins, Renato G.
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn
    Funahashi, Yasuhiro
    Ren, Min
    O'Brien, James P.
    Sherman, Steven I.
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 44 - 53
  • [9] A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas Wilmot
    McCaffrey, Judith C.
    Newbold, Kate
    Allison, Roger
    Martins, Renato
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn A.
    Funahashi, Yasuhiro
    Sellecchia, Rita
    Andresen, Corina
    O'Brien, James P.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Subgroup analysis according to differentiated thyroid cancer histology in phase 3 (SELECT) trial of lenvatinib
    Elisei, R.
    Schlumberger, M.
    Tahara, M.
    Robinson, B.
    Brose, M.
    Dutcus, C.
    Zhu, J.
    Newbold, K.
    Kiyota, N.
    Kim, S. -B.
    Sherman, S.
    Wirth, L.
    Oncology Research and Treatment, 2015, 38 : 25 - 26
1234